Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What a New Look for HIPAA Means for Physicians

No industry looks the same after more than a quarter century of innovation and breakthroughs. Yet in the medical world, HIPAA, a bill passed by the U.S. Congress in 1996, has remained a key regulatory guideline. With innovations in the healthcare sector occurring at a rapid rate, this bill may finally be getting long overdue…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

No industry looks the same after more than a quarter century of innovation and breakthroughs. Yet in the medical world, HIPAA, a bill passed by the U.S. Congress in 1996, has remained a key regulatory guideline. With innovations in the healthcare sector occurring at a rapid rate, this bill may finally be getting long overdue tweaks.

For the first time since 2013, several proposals have been made to change the legislation for 2019.

Changes to Look For

Physicians need to be aware of these updates and how they will affect their practices. All offices will be required to implement these three small modifications into their HIPAA processes:

  • Patients are now able to request digital medical records through digital formats. The clinic will have 30 days, whether on paper or digitally, to produce the information.
  • Patients who pay for services personally and in full may require that the clinic not share treatment information with the patient’s health plan.
  • Clinics can provide immunization information to schools if they are required by law to have it and if a parent/guardian gives written permission.

Other changes include a rise in the maximum penalty for non-compliance to a $50,000 limit, an increase in restrictions on receiving patient authorization to use personal information on marketing campaigns, the simplification of patient authorization for health data for research, and the elimination of insurance companies’ use of genetic information for coverage and cost determinations.

When to Expect Change to Come

A somewhat laborious process, changes to HIPAA regulations follow a specific path. First, the Department of Health and Human Services (HHS) seeks feedback on HIPAA regulations to see which areas are problematic or outdated. After careful consideration of the feedback, the HHS submits a notice of proposed rule changes and queries healthcare industry stakeholders for comments on the suggested modifications. Once feedback and comments have been carefully assimilated, a final rule change is established. At that time, a temporary grace period will begin so that practices can prepare for compliance with the new regulations. That said, it is possible that changes made to HIPAA this year will not be implemented until 2020.

What This Means for Physicians

While these new rules have not been formalized as of yet, they will have a noticeable impact on the day-to-day routines of physicians around the country. Most notably, the decreased tolerance of non-compliance from the government will assure that clinics follow procedure. HIPAA has been in place in various forms for 23 years, so clinics should already be comfortable working within the parameters of the bill. Fortunately, the grace period will give practices the necessary time to rework their daily procedures to incorporate imminent regulatory changes and avoid non-compliance.

ChartLogic believes education about the latest industry changes is critical, not only to business success, but to patient-physician relationships. To read more about the impact of new HIPAA rules, click here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512